Degrader Antibody Conjugates (DACs): Targeted Protein Degraders (TPD) as Next-Generation Antibody Drug Conjugate (ADC) Payloads
- By combining the ability of a TPD to selectively remove a protein of interest with the cell specificity of antibodies, DACs have the potential for greater efficacy and broader therapeutic application than traditional cytotoxic ADC payloads
- Improved safety can be achieved through the layers of specificity provided by degrader selectivity, ligase expression, and antibody targeting
- DACs are more than the sum of their parts and are best optimized combinatorially
- Antibody delivery can expand the applicability of novel ligase ligands in TPD beyond those commonly used for oral small molecules